Ratan Bhat

TL;DR: Results support the idea that kinases are involved in tauopathy progression and that kinase inhibitors may be effective therapeutically and that lithium exerts its effect through GSK-3 inhibition.

TL;DR: AR-A014418 is the first compound of a family of specific inhibitors of GSK3 that does not significantly inhibit closely related kinases such as cdk2 or cdk5 and may have important applications as a tool to elucidate the role of Gsk3 in cellular signaling and possibly in Alzheimer's disease.

TL;DR: The properties of GSK3 are summarized, the potential for such a therapy in AD, and other CNS disorders are discussed, and pharmaceutical companies are investing in finding a selective inhibitor of GK3.

TL;DR: Y(216) phosphorylation of GSK3beta represents an important mechanism by which cellular insults can lead to neuronal death, and in rats, it was increased in degenerating cortical neurons induced by ischemia.

TL;DR: Subacute intraperitoneal injections of AR-A014418 reduced immobility time in rats exposed to the forced swim test, and the hypothesis that lithium may exert its antidepressant effects through inhibition of G SK-3 is supported, and that novel small-molecule GSK-3 inhibitors may be useful for the treatment of bipolar disorder and depression.